Acacia Pharma starts clinical trial with APD515 for Xerostomia
The clinical trial is an ascending dose study of the pharmacokinetics and activity of APD515 in healthy volunteers. Each subject will receive APD515 given topically to the lining of the mouth, at three different dose levels. The volunteers will also take APD515 orally to allow comparison of blood levels between topical and oral APD515. Salivary flow will be measured before and after dosing.
APD515 has been specifically developed by Acacia Pharma to be delivered locally to the salivary glands distributed throughout the oral cavity, minimising absorption into the general circulation. This greatly reduces the potential for side effects, giving APD515 a major advantage over currently approved salivary stimulants, which have to be dosed orally.
Initially, Acacia Pharma intends to develop APD515 in advanced cancer patients, 70-80% of whom suffer from xerostomia either as a direct result of their disease, their chemotherapy or as a consequence of other medicines they are taking, such as tranquilisers, antidepressants, opioid painkillers and H2-blockers. APD515 may be developed in other patient populations once clinical proof of concept has been obtained within the advanced cancer population.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.